fbpx

Press Releases

The Board of Directors of NextCell Pharma AB resolves on a fully guaranteed SEK 25.1 million rights issue

NextCell Pharma AB (“NextCell” or the “Company”) announces that the Board of NextCell Pharma AB has resolved to conduct a fully guaranteed new issue of shares of approximately SEK 25.1…

Cellaviva Sverige May 15, 2020

NextCell Pharma AB publishes its interim report for September 2019 - February 2020

NextCell Pharma AB (publ) (NXTCL) today announces that its Interim report for the period September 1, 2019 – February 29, 2020 now is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-reports Second quarter…

Cellaviva Sverige April 29, 2020

NextCell in discussions about patients with covid-19

NextCell Pharma AB (“NextCell”) announces that parallel discussions with several hospitals have been initiated to treat patients with covid-19, the severe respiratory tract infection caused by the new coronavirus, with…

Cellaviva Sverige March 20, 2020

The stem cell company NextCell Pharma is preparing for a pivotal phase III trial

NextCell Pharma AB (“NextCell”) announces that CEO Mathias Svahn will present a status update of the ongoing clinical trials at the Stockholm Corporate Finance Life Science Seminar held at Berns…

Cellaviva Sverige March 11, 2020

The stem cell company NextCell Pharma participates as a reference laboratory in NIBSC study

NextCell Pharma AB (“NextCell”) announces today, that it has acted as a reference laboratory to assist National Institute for Biological Standards and Control (NIBSC) in the development of a reference…

Cellaviva Sverige February 21, 2020

Participates in innovation projects for cell-based products

NextCell Pharma AB (NextCell) a0nnounces they are, in collaboration with Research Institutes of Sweden (RISE) and Your Special Delivery Service, participating in a CAMP organized project titled: ‘Establishing a non-dry…

Cellaviva Sverige February 10, 2020

NextCell to present its progress at Swiss Nordic Bio 2020

NextCell Pharma AB (“NextCell”) presented, in December 2019, efficacy data of ProTrans stem cells in an interim analysis of the ongoing phase I/II trial, ProTrans-1. Patients receiving medium or high…

Cellaviva Sverige February 4, 2020

Interim Report 1 2019/2020

NextCell Pharma AB today publish the Interim Report 1 for the period September 1 – November 30, 2019. “NextCell”, “NXTCL” or “Company” refer to NextCell Pharma AB with organization number…

Cellaviva Sverige January 31, 2020

Extended permission from the Medical Products Agency

NextCell Pharma AB (“NextCell”) announces that they have been granted with an extended wholesale distribution authorization from the Medical Products Agency. In October, the NextCell operation were subject to a…

Cellaviva Sverige December 11, 2019

Promising Results from clinical trial with ProTrans stem cells

NextCell Pharma AB (“NextCell”) announces today that the primary efficacy measures have reached significance in the dose-escalation phase of the company’s clinical trial. After one year follow-up, the six patients…

Cellaviva Sverige December 4, 2019

A part of Vision-driven Health

NextCell Pharma AB (“NextCell”) announces that it is chosen as one of the collaborators in the newly Vinnova funded project Vision-driven Health: Sweden a leader in advanced therapies in 2030….

Cellaviva Sverige November 22, 2019

Correction: Notice to attend the Annual General Meeting

NextCell Pharma AB (“NextCell”) announces that a notice of the Annual General Meeting for the 2018-2019 financial year has been published. Compared to the press release published this morning, corrections…

Cellaviva Sverige November 7, 2019